CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK; “The Company”), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 26,250 shares of its common stock to one newly hired employee, consisting of inducement stock options to purchase an aggregate of 15,000 shares of common stock and inducement
Business Wire Stock Sale/Buyback News
